Insulin resistance and pathological brain ageing

Diabetic Medicine

Volumn 28, Issue 12, 2011, Pages 1463-1475

  Cholerton, B ^a   Baker, L D ^a   Craft, S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Brain; Insulin resistance

Indexed keywords

INSULIN; PLACEBO; ROSIGLITAZONE; SOMATOMEDIN C;

AGE; AGING; ALZHEIMER DISEASE; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIET; DYSLIPIDEMIA; EXERCISE; FAT INTAKE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MILD COGNITIVE IMPAIRMENT; MOLECULAR MECHANICS; MORNING DOSAGE; NERVE DEGENERATION; NEUROBIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE CAVITY; OBESITY; OLFACTORY BULB; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

AGING; BRAIN; DIABETES MELLITUS, TYPE 2; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MILD COGNITIVE IMPAIRMENT; OBESITY; RISK REDUCTION BEHAVIOR;

EID: 81355151398     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03464.x     Document Type: Review

References (182)

1. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997; 18: 1423-1429.
2. Baskin DG, Figlewicz DP, Woods SC, Porte D Jr, Dorsa DM. Insulin in the brain. Annu Rev Physiol 1987; 49: 335-347.
3. Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 1993; 92: 1824-1830.
4. Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MR, Porte D Jr. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 1990; 11: 467-472.
5. Wallum BJ, Taborsky GJ Jr, Porte D Jr, Figlewicz DP, Jacobson L, Beard JC et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 1987; 64: 190-194.
6. Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci 1999; 19: 7300-7308.
7. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272: 827-829.
8. Havrankova J, Schmechel D, Roth J, Brownstein M. Identification of insulin in rat brain. Proc Natl Acad Sci U S A 1978; 75: 5737-5741.
9. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 1991; 36: 343-362.
10. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28: 809-822.
11. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999; 56: 1135-1140.
12. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996; 17: 123-130.
13. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001; 74: 270-280.
14. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006; 27: 451-458.
15. Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999; 274: 34893-34902.
16. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51: 3384-3390.
17. Reagan LP, Gorovits N, Hoskin EK, Alves SE, Katz EB, Grillo CA et al. Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proc Natl Acad Sci U S A 2001; 98: 2820-2825.
18. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 2000; 24: 855-872.
19. Piroli GG, Grillo CA, Reznikov LR, Adams S, McEwen BS, Charron MJ et al. Corticosterone impairs insulin-stimulated translocation of GLUT4 in the rat hippocampus. Neuroendocrinology 2007; 85: 71-80.
20. Apelt J, Mehlhorn G, Schliebs R. Insulin-sensitive GLUT4 glucose transporters are colocalized with GLUT3-expressing cells and demonstrate a chemically distinct neuron-specific localization in rat brain. J Neurosci Res 1999; 57: 693-705.
21. Brant AM, Jess TJ, Milligan G, Brown CM, Gould GW. Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system. Biochem Biophys Res Commun 1993; 192: 1297-1302.
22. El Messari S, Leloup C, Quignon M, Brisorgueil MJ, Penicaud L, Arluison M. Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. J Comp Neurol 1998; 399: 492-512.
23. Livingstone C, Lyall H, Gould GW. Hypothalamic GLUT 4 expression: a glucose- and insulin-sensing mechanism? Mol Cell Endocrinol 1995; 107: 67-70.
24. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177: 125-134.
25. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A 2001; 98: 3561-3566.
26. Figlewicz DP, Szot P, Israel PA, Payne C, Dorsa DM. Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res 1993; 602: 161-164.
27. Kopf SR, Baratti CM. Effects of post-training administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol Learn Mem 1999; 71: 50-61.
28. Greenwood CE, Winocur G. Glucose treatment reduces memory deficits in young adult rats fed high-fat diets. Neurobiol Learn Mem 2001; 75: 179-189.
29. Vanhanen M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL, Hanninen T et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998; 21: 398-402.
30. Convit A, Wolf OT, Tarshish C, de Leon MJ. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci U S A 2003; 100: 2019-2022.
31. Hoyer S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J Neural Transm 2002; 109: 991-1002.
32. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-438.
33. Rivera E, Goldin A, Fulmer N, Tavares R, Wands J, de la Monte S. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer's Disease 2005; 8: 247-268.
34. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561-2570.
35. Townsend M, Mehta T, Selkoe DJ. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007; 282: 33305-33312.
36. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci U S A 2009; 106: 1971-1976.
37. Lee CC, Kuo YM, Huang CC, Hsu KS. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging 2009; 30: 377-387.
38. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004; 24: 11120-11126.
39. Authier F, Posner BI, Bergeron JJ. Insulin-degrading enzyme. Clin Invest Med 1996; 19: 149-160.
40. Kurochkin IV, Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 1994; 345: 33-37.
41. McDermott JR, Gibson AM. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res 1997; 22: 49-56.
42. Qiu W, Walsh D, Ye Z, Vekrellis K, Zhang J, Podlisny M et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-32738.
43. Sudoh S, Frosch MP, Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid β-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002; 41: 1091-1099.
44. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele. Am J Pathol 2003; 162: 313-319.
45. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003; 100: 4162-4167.
46. Perez A, Morelli L, Cresto JC, Castano EM. Degradation of soluble amyloid B-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000; 25: 247-255.
47. Banks WA, Jaspan JB, Kastin AJ. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 1997; 18: 1257-1262.
48. Gerozissis K, Orosco M, Rouch C, Nicolaidis S. Basal and hyperinsulinemia-induced immunoreactive hypothalamic insulin changes in lean and genetically obese Zucker rats revealed by microdialysis. Brain Res 1993; 611: 258-263.
49. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000; 49: 1525-1533.
50. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18: 902-904.
51. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007; 282: 36275-36282.
52. Hong M, Lee V. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-19553.
53. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004; 101: 3100-3105.
54. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003; 23: 7084-7092.
55. Bourdel-Marchasson I, Lapre E, Laksir H, Puget E. Insulin resistance, diabetes and cognitive function: consequences for preventative strategies. Diabetes Metab 2010; 36: 173-181.
56. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 2004; 59: 268-274.
57. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81years. Br Med J 2004; 328: 548.
58. Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 2004; 10: 599-607.
59. Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G et al. Co-morbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 2004; 33: 355-361.
60. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004; 164: 1327-1333.
61. Messier C, Tsiakas M, Gagnon M, Desrochers A, Awad N. Effect of age and glucoregulation on cognitive performance. Neurobiol Aging 2003; 24: 985-1003.
62. Crooks VC, Buckwalter JG, Petitti DB. Diabetes mellitus and cognitive performance in older women. Ann Epidemiol 2003; 13: 613-619.
63. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999; 16: 93-112.
64. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011; 7: 108-114.
65. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 2008; 585: 119-129.
66. Strachan MW, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. Br Med Bull 2008; 88: 131-146.
67. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
68. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-1262.
69. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004; 62: 1972-1976.
70. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
71. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39: 1392-1397.
72. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997; 826: 422-427.
73. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666.
74. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-481.
75. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 2009; 9: 617-630.
76. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008; 585: 97-108.
77. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008; 71: 750-757.
78. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 2009; 66: 315-322.
79. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 2006; 24: 114-127.
80. Mamo JC, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. Ann Clin Biochem 2008; 45: 395-403.
81. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008; 118: 671-682.
82. Jaeger S, Pietrzik CU. Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 2008; 5: 15-25.
83. Smith CC, Betteridge DJ. Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett 2004; 367: 48-50.
84. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 2008; 16: 343-354.
85. Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 2005; 64: 1378-1383.
86. Cedazo-Minguez A, Ismail MA, Mateos L. Plasma cholesterol and risk for late-onset Alzheimer's disease. Expert Rev Neurother 2011; 11: 495-498.
87. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22: 423-436.
88. Schinzari F, Tesauro M, Rovella V, Galli A, Mores N, Porzio O et al. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 299: E947-E952.
89. Centers for Disease Control. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD: National Center for Health Statistics, 2011.
90. Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 2009; 22: 106-111.
91. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 2008; 7: 476-484.
92. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br Med J 2001; 322: 1447-1451.
93. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama Study. Hypertension 2011; 58: 22-28.
94. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000; 21: 57-62.
95. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55.
96. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev 2009; 8: 61-70.
97. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
98. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a US population. J Clin Epidemiol 2004; 57: 1214-1217.
99. Axen KV, Dikeakos A, Sclafani A. High dietary fat promotes syndrome X in nonobese rats. J Nutr 2003; 133: 2244-2249.
100. Bray GA, Lovejoy JC, Smith SR, DeLany JP, Lefevre M, Hwang D et al. The influence of different fats and fatty acids on obesity, insulin resistance and inflammation. J Nutr 2002; 132: 2488-2491.
101. Proietto J, Filippis A, Nakhla C, Clark S. Nutrient-induced insulin resistance. Mol Cell Endocrinol 1999; 151: 143-149.
102. Vessby B, Unsitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 2001; 44: 312-319.
103. López S BB, Pacheco YM, Villar J, Abia R, Muriana FJ. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. Am J Clin Nutr 2008; 88: 638-644.
104. Piers LS, Walker KZ, Stoney RM, Soares MJ, O'Dea K. The influence of the type of dietary fat on postprandial fat oxidation rates: monounsaturated (olive oil) vs saturated fat (cream). Int J Obes Relat Metab Disord 2002; 26: 814-821.
105. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62: 1556-1560.
106. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Body mass index, dementia, and mortality in the elderly. J Nutr Health Aging 2008; 12: 127-131.
107. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71: 1057-1064.
108. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 2000; 106: 467-472.
109. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000; 20: 558-567.
110. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459.
111. Paik JH, Ju JH, Lee JY, Boudreau MD, Hwang DH. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem 2000; 275: 28173-28179.
112. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991: 214-228.
113. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients. J Leukoc Biol 2004; 75: 478-485.
114. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR γ). J Biol Chem 1995; 270: 12953-12956.
115. Pedersen WA, Flynn ER. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Dis 2004; 17: 500-506.
116. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13: 950-958.
117. Park CR, Seeley RJ, Craft S, Woods SC. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000; 68: 509-514.
118. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008; 131: 3311-3334.
119. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-496.
120. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-516.
121. Frey WH 2nd. Intranasal delivery: bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol 2002; 2: 46-49.
122. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002; 7: 1184-1189.
123. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999; 48: 557-563.
124. Reger MA, Watson GS, Frey WH II, Baker LD, Cholerton B, Keeling ML et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006; 27: 451-458.
125. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-1334.
126. Benedict C, Kern W, Schultes B, Born J, Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 2008; 93: 1339-1344.
127. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A et al. Intranasal insulin therapy for Alzheimer Disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2011; [Epub ahead of print].
128. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003; 299: 853-855.
129. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr 2010; 91: 502-509.
130. Salzman R, Manson JE, Griffing GT, Kimmerle R, Ruderman N, McCall A et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. N Engl J Med 1985; 312: 1078-1084.
131. Cunnane SC, Plourde M, Pifferi F, Bégin M, Féart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 2009; 48: 239-256.
132. Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G et al. Dietary fatty acids in dementia and predementia syndromes: epidemiological evidence and possible underlying mechanisms. Ageing Res Rev 2010; 9: 184-199.
133. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 2010; 21: 691-724.
134. Kanoski SE, Davidson TL. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol Behav 2011; 103: 59-68.
135. Cedazo-Minguez A, Wiehager B, Winblad B, Huttinger M, Cowburn RF. Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Aβ) and apoE/Aβ complexes on protein kinase C-alpha (PKC-α) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem Int 2001; 38: 615-625.
136. Schroeder JE, Richardson JC, Virley DJ. Dietary manipulation and caloric restriction in the development of mouse models relevant to neurological diseases. Biochim Biophys Acta 2010; 1802: 840-846.
137. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog Lipid Res 2010; 49: 159-170.
138. Smith PJ, Blumenthal JA. Diet and neurocognition: review of evidence and methodological considerations. Curr Aging Sci 2010; 3: 57-66.
139. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC et al. Diet and risk of dementia: does fat matter?: The Rotterdam Study. Neurology 2002; 59: 1915-1921.
140. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402-1408.
141. Féart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues J-F et al. Adherence to a mediterranean diet, cognitive decline, and risk of dementia. J Am Med Assoc 2009; 302: 638-648.
142. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 2010; 67: 699-706.
143. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66: 216-225.
144. Bayer-Carter JL, Green PS, Montine TJ, Vanfossen B, Baker LD, Watson GS et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol 2011; 68: 743-752.
145. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 2010; 22: 569-579.
146. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol 2011; 10: 12.
147. Archer T. Physical exercise alleviates debilities of normal aging and Alzheimer's disease. Acta Neurol Scand 2011; 123: 221-238.
148. Black MA, Cable NT, Thijssen DH, Green DJ. Impact of age, sex, and exercise on brachial artery flow-mediated dilatation. Am J Physiol Heart Circ Physiol 2009; 297: H1109-H1116.
149. Ainslie PN, Hamlin M, Hellemans J, Rasmussen P, Ogoh S. Cerebral hypoperfusion during hypoxic exercise following two different hypoxic exposures: independence from changes in dynamic autoregulation and reactivity. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1613-R1622.
150. Colbert LH, Visser M, Simonsick EM, Tracy RP, Newman AB, Kritchevsky SB et al. Physical activity, exercise, and inflammatory markers in older adults: findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52: 1098-1104.
151. Kampus P, Kals J, Unt E, Zilmer K, Eha J, Teesalu R et al. Association between arterial elasticity, C-reactive protein and maximal oxygen consumption in well-trained cadets during three days extreme physical load: a pilot study. Physiol Meas 2008; 29: 429-437.
152. Gomez-Pinilla F, Vaynman S, Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur J Neurosci 2008; 28: 2278-2287.
153. Tierney MC, Moineddin R, Morra A, Manson J, Blake J. Intensity of recreational physical activity throughout life and later life cognitive functioning in women. J Alzheimers Dis 2010; 22: 1331-1338.
154. Geda YE, Roberts RO, Knopman DS, Christianson TJ, Pankratz VS, Ivnik RJ et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol 2010; 67: 80-86.
155. Andel R, Crowe M, Pedersen NL, Fratiglioni L, Johansson B, Gatz M. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci 2008; 63: 62-66.
156. Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 2010; 68: 311-318.
157. Maniam J, Morris MJ. Voluntary exercise and palatable high-fat diet both improve behavioural profile and stress responses in male rats exposed to early life stress: role of hippocampus. Psychoneuroendocrinology 2010; 35: 1553-1564.
158. Black JE, Isaacs KR, Greenough WT. Usual vs. successful aging: some notes on experiential factors. Neurobiol Aging 1991; 12: 325-328 discussion: 352-325.
159. Middleton LE, Barnes DE, Lui LY, Yaffe K. Physical activity over the life course and its association with cognitive performance and impairment in old age. J Am Geriatr Soc 2010; 58: 1322-1326.
160. Silver H, Goodman C, Gur RC, Gur RE, Bilker WB. 'Executive' functions and normal aging: selective impairment in conditional exclusion compared to abstraction and inhibition. Dement Geriatr Cogn Disord 2011; 31: 53-62.
161. Smith PA. Attention, working memory and grammaticality judgment in normal young adults. J Speech Lang Hear Res 2011; 54: 918-931.
162. Charlton RA, Barrick TR, Markus HS, Morris RG. The relationship between episodic long-term memory and white matter integrity in normal aging. Neuropsychologia 2010; 48: 114-122.
163. Colcombe SJ, Kramer AF, Erickson KI, Scalf P, McAuley E, Cohen NJ et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci U S A 2004; 101: 3316-3321.
164. van Uffelen JG, Chin APMJ, Hopman-Rock M, van Mechelen W. The effects of exercise on cognition in older adults with and without cognitive decline: a systematic review. Clin J Sport Med 2008; 18: 486-500.
165. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010; 67: 71-79.
166. Middleton L, Kirkland S, Rockwood K. Prevention of CIND by physical activity: different impact on VCI-ND compared with MCI. J Neurol Sci 2008; 269: 80-84.
167. Abbott RD, White LR, Ross GW, Masaki KH, Curb JD, Petrovitch H. Walking and dementia in physically capable elderly men. J Am Med Assoc 2004; 292: 1447-1453.
168. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P et al. Exercise is associated with reduced risk for incident dementia among persons 65years of age and older. Ann Intern Med 2006; 144: 73-81.
169. Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med 2001; 161: 1703-1708.
170. Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. J Appl Physiol 2006; 101: 1237-1242.
171. Colcombe S, Erickson K, Raz N, Webb A, Cohen N, McAuley E et al. Aerobic fitness reduces brain tissue loss in aging humans. J of Gerontol: Med Sci 2003; 58A: 176-180.
172. Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci 2006; 61: 1166-1170.
173. Voss MW, Prakash RS, Erickson KI, Basak C, Chaddock L, Kim JS et al. Plasticity of brain networks in a randomized intervention trial of exercise training in older adults. Front Aging Neurosci 2010; 2: pii: 32.
174. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 2011; 108: 3017-3022.
175. Ogoh S, Fisher JP, Young CN, Fadel PJ. Impact of age on critical closing pressure of the cerebral circulation during dynamic exercise in humans. Exp Physiol 2011; 96: 417-425.
176. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci 2003; 14: 125-130.
177. Teixeira CV, Gobbi LT, Corazza DI, Stella F, Costa JL, Gobbi S. Non-pharmacological interventions on cognitive functions in older people with mild cognitive impairment (MCI). Arch Gerontol Geriatr 2011; [Epub ahead of print].
178. Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis 2005; 7: 235-239 discussion: 255-262.
179. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. J Am Med Assoc 2008; 300: 1027-1037.
180. Miller LA, Spitznagel MB, Busko S, Potter V, Juvancic-Heltzel J, Istenes N et al. Structured exercise does not stabilize cognitive function in individuals with mild cognitive impairment residing in a structured living facility. Int J Neurosci 2011; 121: 218-223.
181. Honea RA, Thomas GP, Harsha A, Anderson HS, Donnelly JE, Brooks WM et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis Assoc Disord 2009; 23: 188-197.
182. Eggermont LH, Swaab DF, Hol EM, Scherder EJ. Walking the line: a randomised trial on the effects of a short-term walking programme on cognition in dementia. J Neurol Neurosurg Psychiatry 2009; 80: 802-804.